Showing 3531-3540 of 4164 results for "".
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- New Visionix VX65 Digital Phoropter Helps ECPs Meet Social Distancing Recommendationshttps://modernod.com/news/new-visionix-vx65-digital-phoropter-helps-ecps-meet-social-distancing-recommendations/2477756/Luneau Technology USA announced the expansion of its Visionix product line with the addition of the Visionix VX65 digital phoropter. With the majority of refractions are still being conducted with a manual phoropter, the VX65 provides a smooth transition for eye care professionals looking to init
- VisionCare Announces CE Mark Approval of the Tsert-SI Delivery System for the CentraSight Treatment Programhttps://modernod.com/news/visioncare-announces-ce-mark-approval-of-the-tsert-si-delivery-system-for-the-centrasight-treatment-program/2477744/VisionCare has received CE Mark for the Tsert-SI delivery system for the CentraSight treatment program, which includes the Implantable Miniature Telescope (by Dr. Isaac Lipshitz). The Tsert-SI delivery system includes a pre-loaded telescope implant injector, which only requires a 6.5mm incision,
- Santen: VISIONARY Study Demonstrates Effectiveness of Tafluprost/Timolol Combination Therapy in Open-Angle Glaucomahttps://modernod.com/news/santen-visionary-study-demonstrates-effectiveness-and-tolerability-of-tafluprost-timolol-combination-therapy-in-open-angle-glaucoma/2477305/Santen has announced that the results of its real world evidence study, VISIONARY, have been published in Advances in Therapy. The study, which was conducted in 12 countries from across Europe with up to 6-mo
- VSP Global Enters Into Definitive Agreement To Acquire Visionworkshttps://modernod.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/VSP Global announced that it has entered into a definitive agreement to acquire San Antonio, Texas-based Visionworks, which has more than 700 stores in 40 states. The Visionworks acquisition will be the single largest VSP network investment in the company’s
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b
- Ziemer USA Sponsors Visionary Leader Award at OWL Meetinghttps://modernod.com/news/ziemer-usa-sponsors-visionary-leader-award-at-owl-meeting/2479819/Ziemer USA has announced it is sponsoring the Visionary Leader award, presented at the OWL Signature Event and Awards Ceremony. The OWL (Ophthalmic World Leaders) Visionary Leader award honors an individual who has pa
- Low-Dose Atropine Shows Promise in Slowing Childhood Myopia, Real-World Study Findshttps://modernod.com/news/low-dose-atropine-shows-promise-in-slowing-childhood-myopia-real-world-study-finds/2486653/A new clinical study published in Frontiers in Pharmacology adds to growing evidence that low-dose atropine eye drops can
- VIEW Optometry Launches Doctor-Led Alliance to Protect Independent Optometry Practiceshttps://modernod.com/news/view-optometry-launches-doctor-led-alliance-to-protect-independent-optometry-practices/2485609/Key Takeaways VIEW Optometry is a new, doctor-founded alliance committed to protecting clinical aut
- Ocuphire Completes Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopiahttps://modernod.com/news/ocuphire-completes-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-combination-with-low-dose-pilocarpine-for-treatment-of-presbyopia/2479197/Ocuphire Pharma announced that it has completed enrollment in the VEGA-1 phase 2 clinical trial (